Brainsway

BWAY

Market cap $563M

Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access to transformative care Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay with leading North American mental health providers to raise awareness and expand access to transformative care

BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript

Brainsway NASDAQ: BWAY reported a strong start to 2026, with first-quarter revenue rising 35% year over year as the company expanded placements of its Deep TMS systems and continued to build its recurring revenue base.

R evenue grew approximately   35 % y ear- o ver- y ear to   $1 5 .5 million  for Q1 2026

Here is how Brainsway Ltd. Sponsored ADR (BWAY) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.

Brainsway (BWAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

BURLINGTON, Mass. and JERUSALEM, April 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its first quarter 2026 financial results and recent operational highlights before the open of the U.S. financial markets on Wednesday, May 13, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.

BrainsWay continues to deliver strong growth and margin improvement, supported by investments in TMS service providers and recurring revenue expansion. BWAY's accelerated protocol and expanded indications, including adolescent depression, are supportive of further growth. TMS is a relatively expensive treatment option though with a high patient burden, making the impeding entry of psychedelics (psilocybin, LSD, DMT) into the market a serious threat.

Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access to non‑drug mental health treatments Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access to non‑drug mental health treatments